DAWN

Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) CFO Charles York II sold 4,062 shares of the business's stock in a transaction on Monday, November 17th. The shares were sold at an...

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) insider Adam Dubow sold 4,319 shares of the company's stock in a transaction dated Monday, November 17th. The stock was sold at an...

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) CEO Jeremy Bender sold 15,894 shares of the business's stock in a transaction that occurred on Monday, November 17th. The shares were...

The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 161.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) was the recipient of unusually large options trading on Thursday. Stock investors purchased 3,055 call options on the stock. This is...

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down - Time to Sell...

Mersana surged even as multiple firms downgraded the stock following Day One’s acquisition agreement.

Day One Biopharmaceuticals plans to acquire Mersana Therapeutics in a deal worth up to $285 million to expand its cancer drug portfolio.read more...

(RTTNews) - Mersana Therapeutics, Inc. (MRSN), a biopharmaceutical company, Thursday, announced that it has entered a definitive agreement to be acquired by Day One Biopharmaceuticals through a...